Diagnosing Parkinson's disease (PD) and tracking its progression may require the combination of reliable biomarkers. Among them, both serum uric acid (UA) and dopamine transporter (DaT) binding deserve more investigations.

Aims of the study

We aimed to investigate the relationship between serum UA levels and DaT availability in newly diagnosed, drug-naïve PD patients, by means of semiquantitative [(123) I]FP-CIT-SPECT.

Methods

We recruited 52 newly diagnosed, drug-naïve PD patients, and performed serum UA dosage and [(123) I]FP-CIT-SPECT.

Results

Pearson's correlation analysis showed that UA levels were significantly higher in patients with higher averaged, ipsilateral and contralateral DaT binding in caudate, putamen, and striatum.

Conclusions

We showed, for the first time, by regional semiquantitative analysis of DaT binding in PD patients that UA levels significantly correlates with the severity of dopaminergic impairment in caudate, putamen, and striatum. This study broadens our knowledge on the importance of UA as a biomarker of PD.

References

1Gerlach M, Maetzler W, Broich K et al. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 2012; 119: 39–52.
10.1007/s00702-011-0682-x
CAS PubMed Web of Science® Google Scholar
2Alonso A, Rodríguez LA, Logroscino G, Hernán MA. Gout and risk of Parkinson disease: a prospective study. Neurology 2007; 69: 1696–700.
10.1212/01.wnl.0000279518.10072.df
PubMed Web of Science® Google Scholar
3Ascherio A, Lewitt PA, Xu K et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66: 1460–8.
10.1001/archneurol.2009.247
PubMed Web of Science® Google Scholar
4Schwarzschild MA, Schwid SR, Marek K et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008; 65: 716–23.
10.1001/archneur.2008.65.6.nct70003
PubMed Web of Science® Google Scholar
5Constantinescu R, Andreasson U, Holmberg B, Zetterberg H. Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies. Acta Neurol Scand 2013; 127: e8–12.
10.1111/ane.12012
CAS PubMed Web of Science® Google Scholar
6Schlesinger I, Schlesinger N. Uric acid in Parkinson's disease. Mov Disord 2008; 23: 1653–7.
10.1002/mds.22139
CAS PubMed Web of Science® Google Scholar
7Kumral E, Karaman B, Orman M, Kabaroglu C. Association of uric acid and carotid artery disease in patients with ischemic stroke. Acta Neurol Scand 2014; 130: 11–7.
10.1111/ane.12208
CAS PubMed Web of Science® Google Scholar
8Schwarzschild MA, Marek K, Eberly S et al. Serum urate and probability of dopaminergic deficit in early “Parkinson's disease”. Mov Disord 2011; 26: 1864–8.
10.1002/mds.23741
PubMed Web of Science® Google Scholar
9Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–4.
10.1136/jnnp.55.3.181
CAS PubMed Web of Science® Google Scholar
10Fahn S, Elton RL, UPDRS Program Members. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease, vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987; 153–63.
Google Scholar
11Varrone A, Pellecchia MT, Amboni M et al. Imaging of dopaminergic dysfunction with 123I-FP-CIT SPECT in early-onset parkin disease. Neurology 2004; 63: 2097–103.
10.1212/01.WNL.0000145765.19094.94
CAS PubMed Web of Science® Google Scholar
12Scherfler C, Schwarz J, Antonini A et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007; 22: 1229–38.
10.1002/mds.21505
CAS PubMed Web of Science® Google Scholar
13Ravina B, Marek K, Eberly S et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord 2012; 27: 1392–7.
10.1002/mds.25157
CAS PubMed Web of Science® Google Scholar
14Nissen T, Malek N, Grosset KA et al. Baseline [(123) I]FP-CITSPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease. Acta Neurol Scand 2014; 129: 204–8.
10.1111/ane.12178
CAS PubMed Web of Science® Google Scholar
15Contrafatto D, Mostile G, Nicoletti A et al. [(123) I]FP-CIT-SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism. Acta Neurol Scand 2012; 126: 12–6.
10.1111/j.1600-0404.2011.01583.x
CAS PubMed Web of Science® Google Scholar
16 Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014; 71: 141–50.
10.1001/jamaneurol.2013.5528
PubMed Web of Science® Google Scholar

Citing Literature

All articles

Uric acid relates to dopamine transporter availability in Parkinson's disease

Abstract

Background

Aims of the study

Methods

Results

Conclusions

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Uric acid relates to dopamine transporter availability in Parkinson's disease

Abstract

Background

Aims of the study

Methods

Results

Conclusions

References

Citing Literature

References

Related

Information